NanoPass Technologies Ltd. ("NanoPass"), a pioneer in intradermal (into-the-skin or ID) vaccine delivery solutions, is collaborating with the US Center of Disease Control and prevention (CDC) in conducting a large phase 3 trial of polio vaccine in infants in South East AsiaThis collaboration is a

read more>>

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, announced it has reached its enrollment goal of 270 for its pivotal Phase 3 ONTIME trial of rigosertib in patients with myelodysplastic

read more>>

Once famously described as "orphan diseases, too small to be noticed, too small to be funded" in the Hollywood drama Lorenzo's Oil, rare diseases are getting unprecedented attention today among drug manufacturers, who are ramping up research efforts and marketing new medicines that promise fuller

read more>>

Isis Pharmaceuticals, Inc. announced that is has earned a $3.5 million milestone payment from Biogen Idec associated with the dosing of the first patient in a Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy (SMAThe Phase 2 study of ISIS-SMNRx is an open-label, multiple-dose, do

read more>>

One afternoon a week, usually on a Tuesday, a nurse arrives at the Elmwood Park, N.J., home of Jeff and Deena Leider to give their sons, Justin and Jason, their “muscle juice.” On each visit, she carefully inspects a handful of vials, empties them into an intravenous bag, and calibrates a pump

read more>>

Pulmonary hypertension (PH), a rare and life-threatening lung disease, has gone from rapidly fatal to treatable with nine drugs developed in just the past 20 years, a phenomenal record for a rare condition. Growth in the understanding and treatment of PH reflects the dramatic progress possible Pro

read more>>

United Spinal Association and other advocates have combined efforts to ensure that people living with disabilities in Washington State have access to properly configured wheelchairs and other mobility equipment or "complex rehab technology"– that is critical to their quality of life and On May 8

read more>>

Eli Lilly and Company announced Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL). The study failed to show a statistically significant increase compared

read more>>

Alnylam Pharmaceuticals, Inc. and Genzyme, a Sanofi company, announced that they have formed an exclusive alliance to develop and commercialize RNAi therapeutics targeting transthyretin (TTR) for the treatment of transthyretin-mediated amyloidosis (ATTR) in Japan and other Asia-Pacific countries.

read more>>

Insmed Incorporated ("Insmed" or the "Company"), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat patients battling serious lung diseases that are often life-threatening, announced that Will Lewis, President and Chief Executive Officer of A l

read more>>